Ondasetron versus haloperidol for the treatment of postcardiotomy delirium: a prospective, randomized, double-blinded study

To investigate the controlling efficacy of ondasetron and haloperidol in regard to the postcardiotomy delirium. We included in this prospective, randomized, double-blinded study 80 patients who developed delirium after heart surgery with the application of heart lung-machine. The patients were divid...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cardiothoracic surgery 2012-03, Vol.7 (1), p.25-25, Article 25
Hauptverfasser: Tagarakis, Georgios I, Voucharas, Christos, Tsolaki, Fani, Daskalopoulos, Marios E, Papaliagkas, Vassilios, Parisis, Charalampos, Gogaki, Eleni, Tsagalas, Iotalias, Sataitidis, Iotalias, Tsolaki, Magda, Tsilimingas, Nikolaos B
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To investigate the controlling efficacy of ondasetron and haloperidol in regard to the postcardiotomy delirium. We included in this prospective, randomized, double-blinded study 80 patients who developed delirium after heart surgery with the application of heart lung-machine. The patients were divided into two, equally-sized groups, which on detection of delirium received ondasetron 8 mg iv or haloperidol 5 mg iv respectively. The statistical analysis compared the baseline and demographic characteristics of the two groups (age, gender, comorbidities, years of education, type of surgery etc.). Both ondasetron and haloperidol had very good delirium controlling effects, without statistically significant differences. DISCUSSION-CONCLUSIONS: Ondasetron and haloperidol are efficient agents as far as the treatment of postcardiotomy delirium is concerned. As, in addition, ondasetron bares milder side-effects, we believe this could be the agent of choice in patients developing postcardiotomy delirium in the future.
ISSN:1749-8090
1749-8090
DOI:10.1186/1749-8090-7-25